Check out our latest podcast episode on global oil & gas investments. Watch now!
Sales & Support: +1 800 762 3361
Member Resources
Industrial Info Resources Logo
Global Market Intelligence Constantly Updated Your Trusted Data Source for Industrial & Energy Market Intelligence
Home Page

Gilead Bolsters Cancer Portfolio with $21 Billion Immunomedics Buy, an Industrial Info Market Brief

Gilead Bolsters Cancer Portfolio with $21 Billion Immunomedics Buy, an Industrial Info Market Brief

While the quest for a COVID-19 vaccine garners the most attention in the news, there are obviously a plethora of other conditions that require treatment. Near the top of desired therapeutics are oncology (cancer) drugs. Biotech Gilead recently signed a $21 billion deal to purchase breast cancer drug developer Immunomedics Incorporated.

Login or Register for Instant Access

Subscribe Now!

(All Fields Required)

Related Articles

As a Member, you have access to:

  • Industry News Digest
  • IIR Podcast Episodes
  • Market Outlooks & Conference Events
  • Economic Indicators
View All Member Resources
IIR Logo Globe

Site-wide Scheduled Maintenance for September 27, 2025 from 12 P.M. to 6 P.M. CDT. Expect intermittent web site availability during this time period.

×
×

Contact Us

For More Info!